Aberdeen Group plc Buys 18,490 Shares of Insmed, Inc. $INSM

Aberdeen Group plc increased its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 7.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 253,112 shares of the biopharmaceutical company’s stock after acquiring an additional 18,490 shares during the quarter. Aberdeen Group plc owned approximately 0.12% of Insmed worth $44,052,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. CIBC Private Wealth Group LLC boosted its stake in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the period. CoreCap Advisors LLC purchased a new position in shares of Insmed in the fourth quarter worth $27,000. Stone House Investment Management LLC bought a new stake in Insmed during the 3rd quarter valued at $29,000. SBI Securities Co. Ltd. raised its holdings in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 166 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its position in Insmed by 59.6% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 81 shares during the period.

Insmed Stock Performance

NASDAQ INSM opened at $162.43 on Friday. The firm has a market capitalization of $35.06 billion, a PE ratio of -25.34 and a beta of 1.10. The stock’s 50 day moving average is $150.30 and its 200 day moving average is $166.67. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $212.75. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million during the quarter, compared to the consensus estimate of $263.97 million. During the same quarter last year, the company posted ($1.32) EPS. Insmed’s revenue for the quarter was up 152.6% compared to the same quarter last year. Research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 10,699 shares of the stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $143.52, for a total value of $1,535,520.48. Following the completion of the transaction, the chief executive officer directly owned 301,185 shares in the company, valued at $43,226,071.20. This trade represents a 3.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the transaction, the insider directly owned 51,871 shares of the company’s stock, valued at approximately $7,831,483.58. This trade represents a 27.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 210,059 shares of company stock valued at $33,702,709 over the last 90 days. 3.00% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on INSM shares. Stifel Nicolaus boosted their price objective on shares of Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Bank of America increased their target price on shares of Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. UBS Group cut their target price on Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a research note on Tuesday, January 6th. Roth Mkm upgraded Insmed to a “strong-buy” rating in a report on Friday, January 23rd. Finally, Wells Fargo & Company lowered their price target on Insmed from $208.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, March 23rd. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $212.67.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.